Marker Therapeutics Inc (MRKR)

[dmj3430]

We are supposed to get interim results on the TPIV 200 Triple Negative Breast Cancer trial "Mid-Year 2018". I have written Investor Relations twice asking if they are on track to report results and have had ZERO feed back.

From the 10Q

An independent Data Safety Monitoring Board (DSMB) reviews the safety every quarter in this ongoing Phase II study enrolling women with stage I-III triple-negative breast cancer who have completed initial surgery and chemo/radiation therapy. The randomized four-arm study is evaluating two doses of TPIV200 (a high dose and a low dose), each of which will be tested both with and without immune priming with cyclophosphamide prior to vaccination. Safety reviews are conducted quarterly and have shown no safety issues. The study completed enrollment at the end of 2017, with interim data expected in mid-2018. Details regarding this trial can be found at www.clinicaltrials.gov under identifier numbers NCT02593227 and FRV-002.